Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104739 · ClinicalTrials.gov registry record · Phase 4
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02104739: Completed Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
NCT02104739 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 21 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02104739, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk. Newer anti-diabetic agents - exenatide and saxagliptin - impact lipid metabolism. These medications will be studied for their effect in reducing both postprandial lipid levels and arterial dysfunction.
Primary Outcome
Monocyte NfkB p65 arbitrary units are quantified by densitometric analysis of the Western blots.
Interventions
- OTHER Placebo
- DRUG Saxagliptin
- DRUG Exenatide
- DRUG Exenatide extended-release (ER)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-03 |
| Phase | Phase 4 |
What the finished NCT02104739 record still lists
NCT02104739 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02104739 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02104739 about?
NCT02104739 is a clinical study titled "Effects of Antidiabetic Medications on the Postprandial State in Prediabetes". This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk. Newer anti-diabetic agents - exenatide and saxagliptin - impact lipid metabolism. These medications ...
What is the current status of trial NCT02104739?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2014-04. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02104739?
The interventions under investigation include: Placebo (OTHER), Saxagliptin (DRUG), Exenatide (DRUG), Exenatide extended-release (ER) (DRUG).
Who is sponsoring clinical trial NCT02104739?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02104739's enrollment target sits among peer trials
21 1742nd of 2000 higher than 248 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia